We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense® E3 CGM System has not been tested using insertion sites other than the upper arm.
The Eversense® E3 CGM system will stop sending glucose readings after 180 days. To continue using Eversense®, you will need to have your current sensor removed and a new sensor inserted.
- Width: 37.6 mm
- Length: 48.0 mm
- Thickness: 8.8 mm
You can remove the Eversense® E3 Smart Transmitter from the upper arm at any time, except during calibration. Remember that no data are collected when the smart transmitter is not communicating with the sensor. When you place the smart transmitter back on the sensor site, it may take up to 10 minutes for sensor communication to re-start and for glucose readings to appear in the app.
We find that most people work charging into their daily routine at about the same time each day, for example while taking a shower.
You do not need to change the battery. The Eversense® E3 Smart Transmitter has a rechargeable battery and is reusable for up to one year. After one year, the warranty expires and the transmitter should be replaced with a new transmitter.
To reset the transmitter, follow these steps:
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060